UBS AM
KRYS icon

UBS AM’s Krystal Biotech KRYS Stock Holding History

UBS AM’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Buy
38,697
+1,760
+5% +$526K ﹤0.01% 1071
2026
Q1 		$9.54M Buy
36,937
+3,320
+10% +$883K ﹤0.01% 1209
2025
Q4 		$8.29M Sell
33,617
-168,972
-83% -$35.6M ﹤0.01% 1208
2025
Q3 		$35.8M Sell
202,589
-31,731
-14% -$4.75M 0.01% 667
2025
Q2 		$32.2M Sell
234,320
-341,186
-59% -$50.1M 0.01% 851
2025
Q1 		$104M Buy
575,506
+365,304
+174% +$61.4M 0.03% 527
2024
Q4 		$32.9M Sell
210,202
-14,743
-7% -$2.62M 0.01% 777
2024
Q3 		$40.9M Sell
224,945
-26,817
-11% -$5.17M 0.01% 715
2024
Q2 		$46.2M Buy
251,762
+233,501
+1,279% +$39.2M 0.01% 636
2024
Q1 		$3.25M Sell
18,261
-2,165
-11% -$301K ﹤0.01% 1456
2023
Q4 		$2.53M Hold
20,426
– – ﹤0.01% 1568
2023
Q3 		$2.37M Buy
20,426
+3,633
+22% +$443K ﹤0.01% 1535
2023
Q2 		$1.34M Hold
16,793
– – ﹤0.01% 1869
2023
Q1 		$1.34M Buy
16,793
+1,322
+9% +$104K ﹤0.01% 1869
2022
Q4 		$1.23M Sell
15,471
-701
-4% -$52K ﹤0.01% 1756
2022
Q3 		$1.13M Buy
16,172
+965
+6% +$69.7K ﹤0.01% 1896
2022
Q2 		$998K Hold
15,207
– – ﹤0.01% 1964
2022
Q1 		$1.01M Buy
15,207
+5,014
+49% +$313K ﹤0.01% 2133
2021
Q4 		$713K Buy
10,193
+1,488
+17% +$86.6K ﹤0.01% 2384
2021
Q3 		$454K Hold
8,705
– – ﹤0.01% 2535
2021
Q2 		$592K Sell
8,705
-662
-7% -$46.2K ﹤0.01% 2468
2021
Q1 		$722K Sell
9,367
-1,300
-12% -$94.5K ﹤0.01% 2235
2020
Q4 		$640K Hold
10,667
– – ﹤0.01% 2200
2020
Q3 		$459K Buy
10,667
+5,267
+98% +$229K ﹤0.01% 2182
2020
Q2 		$224K Sell
5,400
-467
-8% -$22.5K ﹤0.01% 2356
2020
Q1 		$254K Buy
5,867
+1,767
+43% +$92.4K ﹤0.01% 2206
2019
Q4 		$227K Buy
+4,100
New +$201K ﹤0.01% 2444

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM's KRYS Position: Q2 2026 in Review

UBS AM increased its Krystal Biotech (KRYS) stake by 4.8% in Q2 2026, buying an estimated $526K and bringing the position to 38,697 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

UBS AM first reported a position in KRYS in Q4 2019 and has held it in 27 quarters since. The position peaked at $104M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • UBS AM held 38,697 shares of Krystal Biotech worth $14.4M as of Q2 2026.
  • UBS AM bought 1,760 Krystal Biotech shares in Q2 2026, an estimated $526K.
  • Krystal Biotech made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1071 holding.
  • UBS AM first reported a position in Krystal Biotech in Q4 2019 and has held it in 27 quarters since.
  • UBS AM's Krystal Biotech position peaked at $104M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.